Medios AG Stock

Equities

ILM1

DE000A1MMCC8

Pharmaceuticals

Market Closed - Xetra 11:36:24 2024-05-23 am EDT Pre-market 02:23:52 am
14.26 EUR -1.52% Intraday chart for Medios AG 14.24 -0.14%
Sales 2024 * 2.02B 2.19B Sales 2025 * 2.11B 2.29B Capitalization 339M 367M
Net income 2024 * 29M 31.35M Net income 2025 * 39M 42.16M EV / Sales 2024 * 0.25 x
Net Debt 2024 * 163M 176M Net Debt 2025 * 37.83M 40.9M EV / Sales 2025 * 0.18 x
P/E ratio 2024 *
12 x
P/E ratio 2025 *
10.4 x
Employees 500
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.14%
1 week+1.13%
Current month+0.71%
1 month-0.97%
3 months-3.12%
6 months-17.19%
Current year-10.09%
More quotes
1 week
13.98
Extreme 13.98
14.72
1 month
13.74
Extreme 13.74
14.90
Current year
13.74
Extreme 13.74
18.00
1 year
13.34
Extreme 13.34
18.28
3 years
13.34
Extreme 13.34
41.60
5 years
13.34
Extreme 13.34
42.00
10 years
7.41
Extreme 7.41
42.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 14-11-05
Director of Finance/CFO 53 21-09-30
Chief Operating Officer 55 17-06-30
Members of the board TitleAgeSince
Chairman 50 14-11-06
Director/Board Member 62 16-09-13
Director/Board Member 63 16-09-13
More insiders
Date Price Change Volume
24-05-23 14.26 -1.52% 32,773
24-05-22 14.48 +3.13% 77,214
24-05-21 14.04 -2.90% 41,979
24-05-20 14.46 -0.14% 117,082
24-05-17 14.48 +2.70% 90,849

Delayed Quote Xetra, May 23, 2024 at 11:36 am EDT

More quotes
Medios AG, formerly Crevalis Capital AG, is a Germany-based company that is active in the pharmacy business. It wholesales, markets, distributes and produces various kinds of goods for pharmacies and other pharmaceutical companies. The Company also provides related services and is engaged in the acquisition and management of other companies from the pharmaceutical industry.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.26 EUR
Average target price
34.75 EUR
Spread / Average Target
+143.69%
Consensus

Quarterly revenue - Rate of surprise